Arvind Remedies to launch new drug

12 Jun 2014 Evaluate

Arvind Remedies has entered into Memorandum of Understanding (MoU) with Adesh University, Punjab, to transfer the patent rights to undertake exclusive manufacturing, marketing and commercialisation of drugs for type-II diabetes, depression, irritable bowel syndrome and coronary heart disease. These drugs will be manufactured in the form of tablets and will be launched in the end of 2017, first in the domestic market which will be followed by the global market.

According to the International Diabetes Federation, 382 million people across the world have diabetes, which is expected to rise to 592 million by 2035. The number of people with type-II diabetes is increasing in every country.

Meanwhile, in order to curb this disease, the company has come up with new drug that is from the botanical source which ensures zero side effects on the health of the patient. The company is expecting this new drug to be available in the markets by mid 2015.

Arvind Remedies is engaged in the manufacturing of pharmaceutical formulations such as tablets, capsules (including soft gels), ointments and liquids. ARL markets its products in the institutional (primarily government organizations) and ethical segments, with institutional segment contributing to 70% of the total revenues.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×